Sugemalimab approval in China makes it only second drug approved globally for ENKTL: GlobalData EP News Bureau Nov 20, 2023 GlobalData forecasts sugemalimab to generate sales of $31 million (patient-based forecast) by 2030 for T-cell lymphomas in China
